IntegroGen

IntegroGen AS develops therapeutics for treatment of cancers due to mutations. These types of cancers are resistant to chemotherapy and are metastatic.  IntegroGen’s compounds are generated by a proprietary platform technology for the detection of compounds that are able to restore the function of mutated proteins. This may offer patients a significantly more safe, practical and economical alternative to gene therapy.